Coronavirus (COVID-19)
Learn more
April 11, 2017
Sponsor: National Cancer Institute (NCI)
Number: SWOG S1207
Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial (Phase III trials are new treatments that have worked well in a small number of patients with a this disease) studies how well giving hormone therapy together with or without Everolimus work in treating patients with breast cancer. High amounts of estrogen (primary female hormone) can cause the growth of breast cancer cells. Hormone therapy using certain treatments may fight breast cancer, by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether hormone therapy is more effective when given with or without Everolimus in treating breast cancer.
Hormonal therapy medicines treat hormone-receptor-positive breast cancers in two ways:
Who’s eligible:
Available at: The Hospital of Central Connecticut, MidState Medical Center, and Hartford Hospital.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.